|
KMID : 0880520200560010006
|
|
Chonnam Medical Journal
2020 Volume.56 No. 1 p.6 ~ p.11
|
|
|
Chimeric Antigen Receptor T Cell Therapy: A Novel Modality for Immune Modulation
|
|
Yoon So-My
Eom Gwang-Hyeon
|
|
|
Abstract
|
|
|
|
Cancer remains a leading cause of death, despite multimodal treatment approaches. Even in patients with a healthy immune response, cancer cells can escape the immune system during tumorigenesis. Cancer cells incapacitate the normal cell-mediated immune system by expressing immune modulation ligands such as programmed death (PD) ligand 1, the B7 molecule, or secreting activators of immune modulators. Chimeric antigen receptor (CAR) T cells were originally designed to target cancer cells. Engineered approaches allow CAR T cells, which possess a simplified yet specific receptor, to be easily activated in limited situations. CAR T cell treatment is a derivative of the antigen-antibody reaction and can be applied to various diseases. In this review, the current successes of CAR T cells in cancer treatment and the therapeutic potential of CAR T cells are discussed.
|
|
|
KEYWORD
|
|
|
CAR T cell, Neoplasms, T-Lymphocytes, Combined Modality Therapy, Ligands
|
|
|
FullTexts / Linksout information
|
|
 
|
|
|
Listed journal information
|
|
 
|